Tuesday , November 5 2024
Home / le News / Swiss research leads to cancer break through

Swiss research leads to cancer break through

Summary:
Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein. © Bogdan Hoda | Dreamstime.comCancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths. This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide. Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling protein and that

Topics:
Investec considers the following as important: , , ,

This could be interesting, too:

Investec writes Swiss National Bank to issue new money

Investec writes End of lifelong widows’ pensions moves closer to reality

Investec writes Swiss government deficit shrinks further

Investec writes Swiss government wants to invest more in bomb shelters

Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein.

Swiss research makes cancer break through CCR7
© Bogdan Hoda | Dreamstime.com

Cancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths.

This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide.

Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling protein and that could be used to develop new drugs to reduce the spread of cancer.

The Paul Scherrer Institute is Switzerland’s largest research institute, with 2,100 staff and an annual budget of around CHF407 million, according to the Institute’s website.

More on this:
Discovery article published in Cell (in English)

For more stories like this on Switzerland follow us on Facebook and Twitter.

About Investec
Investec
Investec is a distinctive Specialist Bank and Asset Manager. We provide a diverse range of financial products and services to our niche client base.

Leave a Reply

Your email address will not be published. Required fields are marked *